BNET Industries
King Pharmaceuticals Inc. (KG) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $2.1B
- Profit
- Dec 31 2007
- $182.9M
- Market Cap
- Oct 09 2008
- $1.9B
Latest News and Analysis
Alpharma Rejects King Pharma's Offer; What Now?
The M & A Researcher submits: Alpharma ALO has announced the rejection of King Pharmaceuticals' KG unsolicited $37 per share offer as "financially inadequate." ALO has also disclosed the following with respect to third-party interest: by The M & A Researcher
Friday Options Update: LEH, SCHW, AKAM, KG, APO, TGT, ORCL, KO
Rebecca Engmann Darst contributed to this report. Lehman Brothers LEH – Shares in Lehman Brothers bounded sharply out of the gate with a 10% gain to $15.09 on speculation that the firm might be bought by Korea Development Bank. The move in Lehman comes a day after respected analyst Richard...
King Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Question-and-Answer SessionThank you. The floor is now open for questions. [Operator Instructions]. Our first question comes from Greg Gilbert of Merrill Lynch. Please state your question. Gregory Gilbert - Merrill Lynch Thanks. Good morning. Can you give us your latest thoughts on the competitive environment in the Thrombin market...
Earnings Preview: King Pharmaceuticals
King Pharmaceuticals KG is expected to report Q2 earnings before market open Thursday Aug. 7, with a conference call scheduled for 11:00 am ET.Guidance Analysts are looking for a profit of 32c on revenue of $397.28M. The consensus is wide, 25c to 37c for EPS, and $361M to $423M for...
King Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Question-and-Answer SessionThank you, Mr. Squicciarino. [Operator Instructions]. And our first question comes from Donald Ellis from Thomas Weisel Partners. Please go ahead. Donald Ellis - Thomas Weisel Partners Thank you, and good morning. First question is regarding SKELAXIN. Year-over-year prescriptions were down about 8.5%, but the revenue reported was...
King Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript
Question-and-Answer SessionThank you Mr. Squicciarino. The floor is now open for questions. [Operator Instructions]. Our first question comes from Corey Davis. Go ahead Corey. Corey Davis - Natexis Bleichroeder Thanks very much. I had a couple... first how would you describe the pricing dynamics in the thrombin market now...
King Pharmaceuticals Inc. Q3 2007 Earnings Call Transcript
Question-and-Answer Session Operator Thank you Mr. Markison. [Operator Instructions]. Our first question comes from Adam Greene of J. P. Morgan, please go ahead. Adam Greene - J.P. Morgan Thanks good morning. First, your gross margin guidance of 72% to...
Additional Resources
Alpharma Board of Directors Unanimously Rejects King Pharmaceuticals' Unsolicited Tender Offer as "Financially Inadequate"
Advises Shareholders Not to Tender Shares as Alpharma Has "Received Expressions of Interest from Multiple Parties" in Pursuing a Transaction Process to Explore Strategic Alternatives Continues with Goal of a Transaction at a Price In Excess of $37.00 Per Share King Continues to Be Invited to...
King Pharmaceuticals Responds to Alpharma Inc
BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE: KG) today issued the following statement in response to an announcement by Alpharma Inc. (NYSE: ALO) regarding King's offer to acquire Alpharma for $37.00 per share in cash. [TABLE OMITTED] On September 12, 2008, King Pharmaceuticals announced that it commenced a...
King Pharmaceuticals Provides Updated Replay Information for Conference Call Regarding Proposed Acquisition of Alpharma
BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE:KG) today held a conference call at 10:00 AM ET to discuss its proposal to acquire Alpharma Inc. (NYSE:ALO) for $33.00 per share in cash. Playback of the conference call and the webcast will be available for replay through the close of...
King Proposes Acquisition of Alpharma for $33 Per Share in Cash
Represents Equity Value of $1.4 Billion Offers a Significant Premium to Alpharma Stockholders Combined Entity Would Create a Leading Specialty Pharmaceutical Company with Greater Commercialization Capabilities, Expanded Portfolio of Pain Management Products and a Strengthened Pipeline BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE: KG)...
Alpharma Responds to Unsolicited Proposal by King Pharmaceuticals, Inc
BRIDGEWATER, N.J. -- Alpharma, Inc. (NYSE: ALO), a global specialty pharmaceutical company, confirmed that it received this morning an unsolicited, non-binding proposal from King Pharmaceuticals, Inc. (NYSE: KG) to acquire all of the outstanding shares of Alpharma for $33.00 per share in cash. Alpharma said today's proposal was identical in...
Pain Therapeutics and King Pharmaceuticals Announce Final Data of REMOXY Phase III Study at World Pain Congress in Scotland
GLASGOW, Scotland -- Pain Therapeutics, Inc. (NASDAQ: PTIE) and King Pharmaceuticals, Inc. (NYSE: KG) today presented the final data set of a previously announced pivotal Phase III study of REMOXY([R]), an investigational drug to treat chronic pain. The final data confirm REMOXY provides effective around-the-clock analgesia within a patented formulation...
BellwetherReport.com Analyst Report on NFS, DVN, KG and MF
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...
King Pharmaceuticals Supports Time To Talk™ Education Campaign
Study Highlights New Trend in Motivation behind Teen Abuse, Program Offers Help for Parents BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE:KG) commends the Partnership for a Drug-Free America([R]) on the second anniversary of the Time To Talk[TM] (www.timetotalk.org) campaign, which encourages parents to talk with their kids about...
CytoDyn on Target with Target for Electronic FDA Application
GLORIETA, N.M. & NEW YORK -- CytoDyn, Inc. (Pink Sheets:CYDY) has selected Target Health, Inc. for the preparation and electronic filing of CytoDyn's upcoming FDA application using Target Health's proprietary e*CRF[R] system. The advantage of Target Health is based on its core expertise in regulatory affairs and clinical research, and...
King Pharmaceuticals Announces Date for Release of Second-Quarter 2008 Financial Results and Conference Call
BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE:KG) reported today that the Company plans to announce its financial results for the second quarter ended June 30, 2008, prior to the market open on Thursday, August 7, 2008. The Company also plans to provide a live conference call which may include discussion...
Sandoz launches ramipril
Sandoz Inc. has introduced ramipril, a generic equivalent of King Pharmaceuticals Inc.'s Altace, in the United States. Sandoz is marketing ramipril capsules in 1.25-mg, 2.5-mg, 5-mg and 10-mg strengths...
Research and Markets: Benchmark Serviers Performance Against Key Rivals In The Ethical Pharmaceutical Sector
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/5e9514/les_laboratoires_s) has announced the addition of the "Les Laboratoires Servier: PharmaVitae Profile" company profile to their offering. This analysis examines the historical and forecast performance for Servier in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio...
Comprehensive Evaluation of Pharmaceutical Wholesalers and Distributors in the UK
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/249b33/pharmaceutical_who) has announced the addition of the "Pharmaceutical Wholesalers & Distributors UK - Portfolio Analysis" report to their offering. The Plimsoll Portfolio Analysis - Pharmaceutical Wholesalers & Distributors is a comprehensive evaluation of the UK market. The revised and...
- Next »
- page 1 of 1
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- Incorporated: 1993
- CEO: Mr. Brian A. Markison
King Pharmaceuticals is a pharmaceutical company that researches, develops, manufactures, markets and sells primarily branded prescription pharmaceutical products for general/family practitioners, internal medicine physicians, neurologists, pain specialists, surgeons and hospitals across the U.S. and in Puerto Rico. Co.'s pharmaceutical products can be divided into the following therapeutic areas: cardiovascular/metabolic, neuroscience, hospital/acute care and other. In addition, Co. manufactures third-party pharmaceutical products under contracts with a variety of pharmaceutical and biotechnology companies.
Key Competitors
King Pharmaceuticals Inc. Company Info
Board of Directors
Mr. Brian A. Markison
Chairman
Mr. Ted G. Wood
Lead Director
Dr. R. Charles Moyer Ph.D.
Mr. D. Greg Rooker
Mr. Earnest W. Deavenport Jr.
Ms. Elizabeth M. Greetham
Mr. Philip A. Incarnati
Dr. Gregory D. Jordan Ph.D.
Contact Information
501 Fifth Street
Bristol, TN
423 989-8000